Dulaglutide is a GLP-1 agonist used to manage type 2 diabetes mellitus. Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events.
- Mechanism
- Curator reviewed · 2 references
Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric emptying.
- Primary indication
- Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus.Curator reviewed · 3 structured indications
- Formula / weight
- C2646H4044N704O836S18 · 59669.81 Da
- First approval
- Canada, 2015 · United States, 2014 · European Union, 2021
- Code names
- LY-2189265
- Brand names
Resolves to
What you can answer from here — as of September 25, 2025
Which drugs share a target with Dulaglutide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account